You are here: Industry Insights > AstraZeneca

News List

AstraZeneca’s Lokelma approved for hyperkalaemia in Japan pharmaceutical-technology
March 27, 2020
The Japanese Ministry of Health, Labour and Welfare has approved AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) for patients with hyperkalaemia, characterised by elevated levels of potassium in the blood.
Cipla receives final approval for generic version of AstraZeneca Pharmaceutical’s Nexium (Esomeprazole for Oral Suspension 10mg, 20mg and 40mg) expresspharma
March 27, 2020
With this, Cipla has become the first company to file for the 10 mg variant strength of the product.
AZ to develop siRNA with Silence Theraputics pharmatimes
March 26, 2020
AstraZeneca has revealed plans to collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases.
COVID-19: AstraZeneca to distribute masks as ASCO goes virtual pharmatimes
March 26, 2020
As of this morning - Wednesday 25th March - the current recorded case count for COVID-19 (coronavirus) in the UK has hit 8,077, with 422 deaths and 135 recoveries.
AstraZeneca to Donate 9 Million Face Masks to Support Healthcare Workers americanpharmaceuticalreview
March 25, 2020
AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic.
Lynparza Granted Orphan Drug Designation in Japan for Pancreatic Cancer americanpharmaceuticalreview
March 23, 2020
AstraZeneca announced Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer.
Imfinzi’s success in ES-SCLC not matched in combo with tremelimumab pharmaceutical-technology
March 18, 2020
AstraZeneca’s Imfinzi (durvalumab) plus standard of care (SoC) chemotherapies caused a sustained, clinically meaningful overall survival (OS) benefit in first line treatment of extensive-stage small cell lung cancer (ES-SCLC).
Cediranib trips up in Lynparza combo ovarian cancer trial pharmatimes
March 16, 2020
AstraZeneca and MSD have reported results from the Phase III GY004 trial, in which potential new medicine cediranib, when added to Lynparza (olaparib), did not meet the trial’s primary endpoint.
AstraZeneca gets marketing permission for leukaemia drug in India expresspharma
March 13, 2020
AstraZeneca Pharma has received approval from India’s drug regulator to market Acalabrutinib 100mg capsules, medicine for the treatment of chronic lymphocytic leukaemia.
Imfinzi cancer combo falls short in DANUBE trial pharmatimes
March 09, 2020
AstraZeneca has released an update from its Phase III DANUBE trial, assessing Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page